Feb 2, 2015 2 min read

CANONSBURG – Generic drugmaker Mylan Inc. said Monday it has signed an agreement to acquire Famy Care Limited, an India-based specialty women’s health care company with global leadership in generic oral contraceptive products.

According to a press release, Southpointe-based Mylan said its Mylan Laboratories Ltd. subsidiary in India would pay $750 million in cash plus additional contingent payments of up to $50 million.

The two companies have done business since 2008.

Mylan said the acquisition will build on its existing partnerships with Famy Care in North America, Europe and Australia, and will provide it with an enhanced, vertically integrated platform that will accelerate the company’s growth in the global women’s health care space.

Mylan said the transaction especially complements its pending acquisition of Abbot’s non-U.S. developed markets specialty and branded generics business, which also includes a women’s health care portfolio and sales and marketing capabilities.

Mylan also said the acquisition of the Famy Care businesses will make it a hormonal contraceptives leader in high-growth emerging markets around the world.

The acquisition is expected to close in the second half of 2015, subject to regulatory approvals.

Headquarted in Mumbai, India, Famy Care offers a full range of women’s health products including oral and injectable contraceptives, intra-=uterine devices, tubal rings and hormone-replacement therapy products.